BETNOVATE  C ointment 15 g.

PHARMACEUTICAL FORM
Betnovate-C cream and an ointment containing a 0.1% betamethasone (as betamethasone valerate) and 3% kliokvinol. Betnovate-C cream is homogeneous, with straw-colored, water-soluble. Betnovate-C ointment is a white to yellow and made of paraffin base.
INDICATIONS
Betamethasone valerate active topical corticosteroid for the treatment of these inflammatory dermatoses, which are normally responsive to topical corticosteroid treatment, and is often effective in the less responsive conditions such as psoriasis. Kliokvinol has antibacterial and antifungal deystvie.Betnovate-C is intended for the treatment of the following conditions in which available or possible secondary bacterial and / or fungal infections: eczema in children and adults, including atopic eczema and numulare; Nodular prurigo; psoriasis (excluding widespread plaque psoriasis); nevrodermatozi, seborrheic dermatitis; contact allergic reactions and discoid lupus erythematosus. Betnovate-C can also be used for the treatment of secondarily infected insect bites, and to the anal and genital intertrigo.
 
DOSAGE AND ADMINISTRATION
Betnovate-C is applied as a thin layer on the affected area of the skin two to three times daily until improvement occurs. If necessary, treatment can be continued with a single dose per day or every few days. In the absence of improvement after two to four weeks is recommended reassessment of diagnozata.Betnovate-C Cream is especially suitable for damp and wet the skin surface, a Betnovate-C ointment - for dry, lichenified or surfaces covered with scales.
 
CONTRAINDICATIONS
Betnovate-C is contraindicated in rosacea, acne vulgaris and perioral dermatitis, primary cutaneous viral infections (eg. Herpes simplex and varicella) and in case of hypersensitivity to any component of preparata.Betnovate-C is not indicated for treatment of primary infected skin lesions, caused by the fungus (e. candidiasis and tinea) or bacteria (e.g.. impetigo), as well as genital and perianal pruritus.Betnovate-C is not indicated for the treatment of dermatoses in children less than one year, including dermatitis and rashes caused by diapers.
 
PRECAUTIONS
Long-term continuous topical therapy should preferably be avoided, especially in infants and children, as may occur adrenal suppression, even when administered without okluziya.Pri prolonged treatment with potent topical corticosteroids may occur atrophic changes mainly on face. This must be taken into account in the treatment of diseases such as psoriasis, discoid lupus erythematosus and severe eczema. Where Betnovate-C be used in children or on the face, courses should be limited if possible to five days, the affected areas should be covered with an occlusive prevrazka.Pri application of Betnovate-C on the eyelids should be careful preparation does not enter the eyes due to the risk of glaucoma. Topical corticosteroids for the treatment of psoriasis requires special attention by the physician due to the risk of chronic, development of tolerance, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the secondary generalization kozhata.Vsyako infection requires discontinuation of topical corticosteroids and conducting systemic antimicrobial treatment. Bacterial infection decreases in warming and moisturizing the skin as a result of occlusion, which is why the area should be cleaned before imposing new prevrazka.V If after 7 days of treatment with topical corticosteroids no clinical improvement, the application should be discontinued due to the risk of spreading the infection hidden due to the masking effect of corticosteroids. Betnovate-C can stain hair, skin or clothing. Should be applied to a suitable dressing in order to protect clothing.
Note: Products that contain antimicrobials should not be diluted.
PREGNANCY
There is insufficient clinical data on the safety of Betnovate-C in pregnant women. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intrauterine growth retardation. Therefore, it may be a very small risk of such effects in the human fetus.
SIDE EFFECT
Prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin such as thinning, striae and expansion of surface blood vessels, particularly when occlusive dressings are used and affected skin ganki.Kakto with other topical corticosteroids, prolonged use of large amounts or treatment of extensive uchastachi skin can result in significant systemic absorption, as a result of which signs of hypercortisolism and suppression of the hypothalamic-pituitary-adrenal system. These effects are most likely in infants and children and the use of occlusive dressings. Diapers in infants may have the effect of occlusive prevrazka.Sashtestvuvat messages pigmentation changes and hypertrichosis with the use of topical corticosteroids.
Rarely treatment of psoriasis with corticosteroids (or termination) provoked pustular form .per disease (see Precautions) Usually all forms of Betnovate well tolerated, but if signs of hypersensitivity, treatment should be discontinued immediately.
 
PHARMACEUTICAL PRECAUTIONS
Betnovate-C cream stored at temperatures below 25 ° C. Betnovate-C ointment stored at temperatures below 30 ° C.
 
PACKAGING
Betnovate-C cream and ointment Betnovate-C in tubes of 15 grams.